Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142682 | 1.00 | NR1H4 (0.56) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL13885725 | 0.90 | NR1H4 (0.53) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3976603 | 0.90 | NR1H4 (0.53) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL3976602 | 0.90 | NR1H4 (0.53) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1633388 | 0.85 | MEN1 (0.79) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1634878 | 0.85 | MEN1 (0.79) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL29282944 | 0.82 | NR1H4 (0.67) | NR1H4KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL306311 | 0.81 | ALDH1A1 (0.58) | KMT2ALMNAALDH1A1MAPK1MAPT | |
| SCHEMBL915484 | 0.80 | MEN1 (0.51) | KMT2AMEN1MAPTNPSR1 | |
| SCHEMBL915483 | 0.80 | MEN1 (0.51) | KMT2AMEN1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209612-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-20 | — | — | US | claimed |
| EP-1756053-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | Ranbaxy Laboratories Limited (IN) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118536-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | claimed |
| US-20090209612-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-20 | — | — | US | disclosed |
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-28 | — | — | US | disclosed |
| EP-1756053-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | Ranbaxy Laboratories Limited (IN) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006110918-A1 | PYRROLE COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1643988-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005118536-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
| WO-2004105752-A1 | SUBSTITUTED PYRROLE DERIVATIVES AS HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149605-A1 | Substituted pyrrole derivatives as hmg-coa reductase inhibitors | HMGCR, CYP46A1, GRHPR | NR1H4 100/4885KMT2A 2565/4885MEN1 2619/4885 |
| US-20090209612-A1 | PROCESS FOR THE PREPARATION OF ATORVASTATIN | HMGCR, DHCR7, LDLR | NR1H4 71/4885KMT2A 3482/4885MEN1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.